cumulative probability of new-onset type-2 diabetes
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Robert F Storey, John Deanfield, Stefan James, Ramzi A Ajjan, Niclas Eriksson, David Erlinge, Mark de Belder, Chris P Gale, Azfar Zaman, Robin Hofmann, Linda Mellbin, Kasper Andersen, Yunyun Jiang, Peter A Johansson, Wilhelm Ridderstråle, Anna Maria Langkilde, Ehsan Parvaresh Rizi, Jonas Oldgren, Darren K McGuire
J Am Heart Assoc 14(15) e040327
BACKGROUND: Dapagliflozin improved cardiometabolic outcomes following myocardial infarction in patients without prior type-2 diabetes (T2DM) in the DAPA-MI (dapagliflozin in patients with myocardial infarction) trial. The effect of glycemic status and body mass index (BMI) post-myocardial infarction requires elucidation. METHODS: Participants with T2DM diagnosis, without baseline hemoglobin A1c, or not receiving any study medication, were excluded. Eligible participants were categorized, according to baseline hemoglobin A1c, as normoglycemic (<5.7% [39 mmol/mol]) or prediabetes (5.7 to <6.5% [48 mmol/mol]) and according to baseline BMI (<25, 25 to <30, and ≥30 kg/m2). Hazard ratios (HRs) with 95% CIs and 1-year Kaplan-Meier rates were determined for new-onset T2DM (investigator-reported or hemoglobin A1c ≥6.5%) and New York Heart Association symptom classification during follow-up. RESULTS: Of 4017 DAPA-MI participants, 3425 were eligible. In 1926 with baseline normoglycemia, new-onset T2DM occurred in 0.6% and 1.6% assigned to dapagliflozin and placebo, respectively (hazard ratio, 0.40 [95% CI, 0.15-1.03]); in 1499 with prediabetes at baseline, new-onset T2DM occurred in 10.1% and 13.1%, respectively (hazard ratio, 0.74 [05% CI, 0.55-0.99]; P interaction 0.23). One-year absolute risk reduction for new-onset T2DM was 8.1% in those with both prediabetes and BMI ≥30. Dapagliflozin reduced the occurrence of New York Heart Association class III-IV symptoms, with greater effect in those with prediabetes versus normoglycemia (P interaction 0.009). One-year absolute risk reduction for New York Heart Association class III-IV symptoms was 10.0% in those with both prediabetes and BMI ≥30. CONCLUSIONS: Dapagliflozin reduced the occurrence of new-onset T2DM following myocardial infarction, regardless of baseline hemoglobin A1c or BMI. Dapagliflozin provided greater reduction in heart failure symptom burden in those with prediabetes compared with normoglycemia.
2 个 Figure · 12 个 KM 面板
Figure 3. Cumulative probability of new‐onset type‐2 diabetes occurring during follow‐up in dapagliflozin and placebo groups according to baseline HbA1c or body mass index. New‐onset type‐2 diabetes in (A) the whole subanalysis cohort and (B‐F) subgroups of this cohort with the following baseline characteristics: (B) HbA1c < 5.7%, (C) HbA1c 5.7 to < 6.5%, (D) BMI < 25, (E) BMI 25 to < 30, and (F) BMI ≥30. BMI indicates body mass index; HbA1c, hemoglobin A1c; 1‐yr KM%, Kaplan–Meier cumulative incidence at 1 year; and Dapa, dapagliflozin.
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel B
Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel C
Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel D
Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel E
Panel E 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel F
Panel F 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 6. Cumulative probability of New York Heart Association class III to IV symptoms occurring during follow‐up in dapagliflozin and placebo groups according to baseline HbA1c or body mass index. NYHA class III‐IV symptoms in (A) the whole subanalysis cohort and (B‐F) subgroups of this cohort with the following baseline characteristics: (B) HbA1c < 5.7%, (C) HbA1c 5.7 to < 6.5%, (D) BMI < 25, (E) BMI 25 to < 30, and (F) BMI ≥30. BMI indicates body mass index; 1‐yr KM% indicates Kaplan–Meier cumulative incidence at 1 year; Dapa, dapagliflozin; HbA1c, hemoglobin A1c; and NYHA, New York Heart Association.
Figure 6 · Panel A
Panel A 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 6 · Panel B
Panel B 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 6 · Panel C
Panel C 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 6 · Panel D
Panel D 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 6 · Panel E
Panel E 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 6 · Panel F
Panel F 是同一 Figure 6 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。